Ligation-based detection of genetic variants

• US 10,233,496 B2
• Filed: 10/09/2015
• Issued: 03/19/2019
• Est. Priority Date: 08/06/2010
• Status: Active Grant

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Ariosa Diagnostics Incorporated (Roche Holding AG)
• Inventors: Oliphant, Arnold, Sparks, Andrew, Stuelpnagel, John, Song, Ken
• Primary Examiner(s): Dauner, Joseph G.
• Application Number:
  US14/880,093
• Publication Number:
  US 20160108474A1
• Time in Patent Office: 1,257 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6862 Ligase chain reaction [LCR]
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2525/155 incorporating/generating a new priming site
• CPC Class Codes: C12Q 2525/161 incorporating target specific and non-target specific sites
• CPC Class Codes: C12Q 2533/107 Probe or oligonucleotide ligation
• CPC Class Codes: C12Q 2535/131 Allele specific probes
• CPC Class Codes: C12Q 2561/125 Ligase Detection Reaction [LDR]
• CPC Class Codes: C12Q 2565/514 characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
• CPC Class Codes: C12Q 2565/543 characterised by the use of two or more capture oligonucleotide primers in concert, e.g. bridge amplification
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation—, e.g., the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides—combined with detection of levels of particular genomic regions using array hybridization.

Claims

1. A method for detecting a fetal aneuploidy and alleles at polymorphic loci in a maternal plasma or serum sample, comprising the steps of:

providing a maternal plasma or serum sample;

introducing between 48 and 2000 first sets of first and second fixed sequence oligonucleotides to the maternal plasma or serum sample under conditions that allow the between 48 and 2000 first sets of first and second fixed sequence oligonucleotides to specifically hybridize to non-polymorphic regions on a first chromosome of interest, wherein each first set comprises a binding region that binds selectively to a first array feature and a region that binds to a first label, and wherein melting temperatures (T_ms) of first fixed sequence oligonucleotides of each first set of first and second fixed sequence oligonucleotides vary in a range of two degrees centigrade;

introducing between 48 and 2000 second sets of first and second fixed sequence oligonucleotides to the maternal plasma or serum sample under conditions that allow the between 48 and 2000 second sets of first and second fixed sequence oligonucleotides to specifically hybridize to non-polymorphic regions on a second chromosome of interest, wherein each second set comprises a binding region that binds selectively to the first array feature and a region that binds to a second label that is different from the first label, and wherein T_ms of first fixed sequence oligonucleotides of each second set of first and second fixed sequence oligonucleotides vary in a range of two degrees centigrade;

introducing between 48 and 2000 third sets of first, second and third fixed sequence oligonucleotides to the maternal plasma or serum sample under conditions that allow the between 48 and 2000 third sets of first, second and third fixed sequence oligonucleotides to specifically hybridize to polymorphic regions of interest, wherein each third set comprises a first fixed sequence oligonucleotide specific for a first allele and a third label, a second fixed sequence oligonucleotide specific for a second allele and a fourth label different from the third label, a binding region that binds selectively to an array feature, and wherein there is a different binding region and a different array feature for each polymorphic region;

hybridizing the first, second and third sets of fixed sequence oligonucleotides to nucleic acids in the maternal plasma or serum sample;

ligating the hybridized fixed sequence oligonucleotides to create contiguous ligation products complementary to the non-polymorphic and polymorphic regions of interest;

introducing the contiguous ligation products to an array comprising array features complementary to the binding regions in the contiguous ligation products;

detecting hybridization of the contiguous ligation products from the first and second sets of fixed sequence oligonucleotides to the array by detection of the first and second labels at the first array feature;

determining a frequency of the first and second chromosomes of interest based on the level of hybridization of the first and second sets of fixed sequence oligonucleotides;

detecting a fetal aneuploidy based on the frequency of the first and second chromosomes of interest;

detecting hybridization of the contiguous ligation products from the third sets of fixed sequence oligonucleotides to the array by detecting the third and fourth labels at the other array features; and

determining a frequency of the first and second alleles at each polymorphic locus based on level of hybridization of the third sets of fixed sequence oligonucleotides comprising the third and fourth labels at the other array features.

2. The method of claim 1, further comprising amplifying the contiguous ligation products prior to introduction to the array.

3. The method of claim 2, wherein one or both of the first or second fixed sequence oligonucleotides of each set comprise universal primer regions.

4. The method of claim 1, further comprising introducing one or more bridging oligonucleotides for each set under conditions that allow the bridging oligonucleotides to hybridize to complementary regions in the non-polymorphic and polymorphic regions on the chromosomes of interest between the first and second fixed sequence oligonucleotides to create hybridization products.

5. The method of claim 4, wherein the hybridization products of the fixed sequence oligonucleotides and the non-polymorphic and polymorphic regions on the chromosomes of interest to which they hybridize are isolated prior to introduction of the bridging oligonucleotides.

6. The method of claim 4, wherein the one or more bridging oligonucleotides are introduced simultaneously with the fixed sequence oligonucleotides.

7. The method of claim 1, wherein the first, second, third and fourth labels are fluorescent labels.

8. The method of claim 1, wherein the method is carried out for at least 100 sets of fixed sequence oligonucleotides complementary to non-polymorphic regions on the first chromosome and at least 100 sets of fixed sequence oligonucleotides complementary non-polymorphic regions on the second chromosome.

9. The method of claim 1, wherein the method is carried out for at least 200 sets of fixed sequence oligonucleotides complementary to non-polymorphic regions on the first chromosome and at least 200 sets of fixed sequence oligonucleotides complementary non-polymorphic regions on the second chromosome.

10. The method of claim 1, wherein the method is carried out for at least 500 sets of fixed sequence oligonucleotides complementary to non-polymorphic regions on the first chromosome and at least 500 sets of fixed sequence oligonucleotides complementary non-polymorphic regions on the second chromosome.

11. The method of claim 1, wherein the method is carried out for at least 192 third sets of first, second and third fixed sequence oligonucleotides to the maternal plasma or serum sample under conditions that allow at least 192 third sets of first, second and third fixed sequence oligonucleotides to specifically hybridize to polymorphic regions of interest.